CHEST 2024: Updates in IPF and PAH Care

Author(s):

Key Takeaways

Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Personalized treatment approaches are needed to address individual patient variability in IPF and PAH.
Enhanced understanding of pathophysiological mechanisms is crucial for novel therapeutic target development.

Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management (particularly chronic cough), and developing more effective, accessible therapies to enhance long-term patient outcomes.

Now Viewing

EP: 1.CHEST 2024: Updates in IPF and PAH Care

EP: 2.Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry

1. Coming into CHEST 2024, what would you consider to be the largest unmet needs in the treatment and management of IPF and PAH?